Tranquis, a breakthrough clinical-stage biopharmaceutical company, is developing a portfolio of promising small molecules with a unique mechanism of action capable of reprogramming dysfunctional myeloid immune cells to restore normal mitochondrial biogenesis, cell homeostasis and function. Our drug candidates “switch” microglia and monocytes from a dysfunctional to a functional state by targeting master regulators of cell energy metabolism, such as PGCIα and other targets. Tranquis’ approach has the potential to revolutionize the management of a broad range of mitochondrial and immune-mediated CNS and non-CNS indications, by modifying disease and thereby significantly improving the lives of millions of patients.
Privately Funded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):